We are investigating if continuing cemiplimab treatment helps patients with oligometastatic NSCLC live longer without disease progression after initial therapy. This study compares the effects of cemiplimab to a placebo.
Health conditions and diseases that the clinical trial is designed to study and treat.
Non-small cell lung cancer (NSCLC) is a type of lung cancer that includes several subtypes and is characterized by uncontrolled cell growth in the lungs. It is the most common form of lung cancer, often linked to smoking and environmental factors.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
